Clinical Trials on Symptomatic Hypertrophic Cardiomyopathy (HCM) in Portugal

Total 10 results

Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Portugal, Poland, Hungary, Denmark, Netherlands, Germany, Czechia
Cytokinetics
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM) (SEQUOIA-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
Bristol-Myers Squibb

Active, not recruiting

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Hypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy

Denmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
MyoKardia, Inc.

Completed

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)

Obstructive Hypertrophic Cardiomyopathy

United States, France, Germany, Czechia, Spain, Belgium, Denmark, Portugal, Netherlands, Israel, Poland, United Kingdom, Italy
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

Cardiomyopathy, Hypertrophic

Spain, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Israel, Japan, Netherlands, Norway, Poland, Portugal, United Kingdom, United States, Australia, China, Czechia, India, Italy, Korea, Republic of
Pfizer

Completed

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology (TTRACK)

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Italy, Romania, France, Australia, Austria, Portugal, Slovakia, Slovenia, Spain, United Kingdom
Novo Nordisk A/S

Recruiting

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
Novo Nordisk A/S

Active, not recruiting

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Spain, Portugal, Canada, Czechia, France, Germany, Italy, Japan
Ionis Pharmaceuticals, Inc.
AstraZeneca

Recruiting

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Portugal, Spain, Sweden, United Kingdom, Australia, Greece
Ionis Pharmaceuticals, Inc.

Active, not recruiting

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Australia, Spain, Canada, Germany, Japan, Italy, Israel, Argentina, France, Portugal, Austria, Brazil, Greece, United Kingdom, Czechia, Sweden, Belgium, Denmark, Poland, Puerto Rico

Clinical Trials on Symptomatic Hypertrophic Cardiomyopathy (HCM) in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations